Does Poly-N-Acetyl Glucosamine Patch Use Reduce Arteriovenous Fistula and Graft Failure Rates in Hemodialysis Patients With End-Stage Renal Disease?

Ünalp, Aynur; Colvin, Ryan; Natta, Mark L. Van; Meinert, Curtis L.; Ploth, David W.; Counts, Caroline A.; Shepp, Pamela H.

doi:10.1097/maj.0b013e3181abf66b

Cited by 4 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GlcN has immune regulatory capacity 7 and is used in clinic for immune regulation such as in post transplantation 8. Meanwhile, some side effects of GlcN have been reported,9 such as induction of oxidative stress on beta cells 10, 11.…”

Section: Introductionmentioning

confidence: 99%

Concurrently using rosiglitazone prevents glucosamine‐induced islet β‐Cell apoptosis and dysfunction

Zhang

Tong

Yao

2010

Cell Biochemistry & Function

View full text Add to dashboard Cite

Diabetes has merged as a significant health problem. This study aims to examine the effect of concurrently using rosiglitazone (RSG) on inhibiting glucosamine (GlcN)-induced islet beta cell apoptosis and dysfunction. Using an islet beta cell line, HIT-T15 cells, as a study platform, the inhibitory effect of RSG on GlcN-induced pathophysiological changes in islet beta cells was examined. The results showed that treatment with GlcN induced HIT-T15 cell death via apoptotic pathway, inhibited the expression of Bcl-2 and Bcl-xL, enhanced the expression of Bax, Bid and caspase-3, reduced the production of ATP and decreased in insulin secretion. The changes were in a GlcN dose-dependent manner. Concurrently using RSG with GlcN, the induced pathogenic changes in HIT-T15 cells were abrogated. We conclude that concurrently using RSG can be useful in reducing the GlcN-induced side effects on islet beta cells that has potential to prevent the complications caused by GlcN in the treatment of diabetes.

show abstract

Section: Introductionmentioning

confidence: 99%

Concurrently using rosiglitazone prevents glucosamine‐induced islet β‐Cell apoptosis and dysfunction

Zhang

Tong

Yao

2010

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Therefore, hemostatic pads that may alleviate the need for prolonged vigorous pressure may be beneficial in preserving the functionality of the vascular access. Indeed, one retrospective small study has suggested a lower access failure rate with the use of poly-n-acetyl glucosamine patch (Syvek patch™) (22). In this paper, we describe a prospective crossover study in which we compared the hemostatic efficacy of the C-pads with that of a standard gauze pad (G-pad).…”

Section: Resultsmentioning

confidence: 99%

The hemostatic efficacy of chitosan-pads in hemodialysis patients with significant bleeding tendency

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In Kordestani et al study, there were no complications regarding the use of ChitoHem® at the site of angiography access [6]. Also, the study by Unalp et al showed that the use of poly-n-acetyl glucosamine patch reduces the incidence of thrombosis in the vascular access site [5].…”

Section: Discussionmentioning

confidence: 96%

“…Also, the study by Unalp et al . showed that the use of poly-n-acetyl glucosamine patch reduces the incidence of thrombosis in the vascular access site [ 5 ]. The price of just one HemoFoam® is about 2.5 times higher compared to conventional gauze.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of HemoFoam® and Conventional Gauze Dressing on Hemostasis of Vascular Access Site in Hemodialysis Patients

Bizari

Khoshmohabat

Kordestani

et al. 2019

GMJ

View full text Add to dashboard Cite

Background: Dialysis access puncture wound bleeding after needle extraction at the end of each hemodialysis session is a very important problem. This study evaluated the effect of HemoFoam® compared to conventional gauze dressing on hemostasis of dialysis access puncture wound bleeding in hemodialysis patients. Materials and Methods: This one-group, before-after, clinical-trial was conducted on 60 hemodialysis patients selected by convenience sampling who underwent hemodialysis through arteriovenous fistula in Shahid Rahnemoon Hospital, Yazd, Iran in 2017. After reviewing the eligibility criteria, the study was performed in two separate sessions. In the first session, only HemoFoam® was used while in the second session; the only conventional dressing was used. Time of hemostasis in each puncture wound was evaluated. Data were analyzed by SPSS 22 (IBM SPSS Statistics for Windows, Armonk, NY: IBM Corp, United States) using paired T-test and Chi-square tests. Results: The mean age of the patients was 55.20±14.25 years. Hemostasis was achieved in 76.6% of cases at the arterial access site in the first two minutes in the HemoFoam® group. The mean homeostasis time in the HemoFoam® group was 2.86±1.87 min at the venous access site and 3.15±1.97 min at the arterial access site (P<0.001). The mean homeostasis time in the conventional dressing group was 10.54±6.65 min at venous access site and 12.74±9.28 min at the arterial access site, which was significantly different between the two groups (P<0.001). Conclusion: HemoFoam® is effective in reducing the time of homeostasis in the vascular access site of hemodialysis patients. Therefore, its use in hemodialysis wards is recommended for hemostasis in the dialysis access puncture wound bleeding. [GMJ.2019;8:e1395]

show abstract

Does Poly-N-Acetyl Glucosamine Patch Use Reduce Arteriovenous Fistula and Graft Failure Rates in Hemodialysis Patients With End-Stage Renal Disease?

Cited by 4 publications

References 24 publications

Concurrently using rosiglitazone prevents glucosamine‐induced islet β‐Cell apoptosis and dysfunction

Concurrently using rosiglitazone prevents glucosamine‐induced islet β‐Cell apoptosis and dysfunction

The hemostatic efficacy of chitosan-pads in hemodialysis patients with significant bleeding tendency

Comparison of HemoFoam® and Conventional Gauze Dressing on Hemostasis of Vascular Access Site in Hemodialysis Patients

Contact Info

Product

Resources

About